Is Buying Stock In BioMarin Pharmaceutical Inc. (BMRN) A Good Move Today?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw an upside of 0.94% to close Tuesday at $78.63 after adding $0.73 on the day. The 5-day average trading volume is 1,063,480 shares of the company’s common stock. It has gained $79.49 in the past week. An average of 1,077,420 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,143,208.

BMRN’s 1-month performance is 0.83% or $0.65 on its low of $75.19 reached on 10/04/21. The company’s shares have touched a 52-week low of $71.65 and high of $92.57, with the stock’s rally to the 52-week high happening on 01/08/21. YTD, BMRN has lost -10.33% or -$9.06. However, the current price is down -15.05%% from the 52-week high price.


A Backdoor Way To Profit From Today’s Crypto Bull Market

In any crypto bull market, there's a lot of money to be made.

But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?

This strategy is simply and ridiculously easy.

Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.

Sponsored


Insider Transactions

On Aug 02, 72 days have gone by since the last insider trading activity for BioMarin Pharmaceutical Inc. (BMRN). Davis George Eric (EVP, General Counsel) most recently sold 5,518 shares at $76.69 per share on Aug 02. This transaction cost the insider $423,175. Chief Executive Officer, BIENAIME JEAN JACQUES, sold 8,513 shares at a price of $77.29 on May 10. Then, on May 07, EVP, Chief Financial Officer Mueller Brian sold 6,709 shares at a price of $79.50 per share. This transaction amounted to $533,366.

Valuation Metrics

BioMarin Pharmaceutical Inc. (BMRN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector. The company’s PE ratio for the last five years has touched a high of 203.64 and a low of 16.62. BMRN stock has a beta of 0.52. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.46 while the price-to-book (PB) in the most recent quarter is 3.39, with the price to cash flow ratio at 82.41.

BioMarin Pharmaceutical Inc.’s quick ratio for the period ended June 29 was 3.70, with the current ratio over the same period at 5.30 meaning that BMRN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.25, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 70.70%. The trailing 12-month EBITDA margin is 0.05% while for the period ending June 29; BioMarin Pharmaceutical Inc.’s operating margin was -3.30%. The firm’s gross profit as reported stood at $1.34 billion against revenue of $1.86 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, BioMarin Pharmaceutical Inc.’s cash and short-term investments amounted to $481.86 million against total debt of $1.09 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 14.39% to $501.69 million, while revenue of $486.03 million was 3.12% off the previous quarter. Analysts expected BMRN to announce -$0.11 per share in earnings in its latest quarter, but it posted $0.07, representing a 163.60% surprise. EBITDA for the quarter stood at more than $40.11 million. BMRN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.66 billion, with total debt at $1.09 billion. Shareholders hold equity totaling $183.35 million

Technical Picture

Let’s look briefly at BioMarin Pharmaceutical Inc. (BMRN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 56.92% to suggest the stock is trending Neutral, with historical volatility in this time period at 15.37%.

The stock’s 5-day moving average is $77.87, reflecting a +2.48% or $1.90 change from its current price. BMRN is currently trading +3.23% above its 20-day SMA, -0.62% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +1.58% and -11.31% respectively.

Stochastic %K and %D was 61.17% and 54.19% and the average true range (ATR) pointed at 1.74. The RSI (14) points at 52.99%, while the 14-day stochastic is at 71.82% with the period’s ATR at 1.79. The stock’s 9-day MACD Oscillator is pointing at 0.74 and 0.48 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for BMRN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BMRN as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 16 have offered a “buy” rating.

What is BMRN’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $81.00 and a high of $165.00, with their median price target at $105.00. Looking at these predictions, the average price target given by analysts is for BioMarin Pharmaceutical Inc. (BMRN) stock is $111.16.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam